Listed

U S Physical Therapy Inc: Form 10-Q for the period ended Jun 30, 2016

Filed with the SEC on Aug 5, 2016 and accepted by EDGAR at Aug 5, 2016, 10:02 ET.

Share

Management's discussion and analysis

As filed, 30,719 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2016; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2015 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2015.

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

EXECUTIVE SUMMARY

Our Business

We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of June 30, 2016, we operated 516 clinics in 42 states.

We also manage physical therapy facilities for third parties, primarily physicians, with 22 third-party facilities under management as of June 30, 2016.

During the six months of 2016 and the year ended 2015, we acquired the following clinic groups:

Date 2016 % Interest Acquired Number of Clinics
February 2016 Acquisition February 29 55% 8
2015
January 2015 Acquisition January 31 60% 9
April 2015 Acquisition April 30 70% 3
June 2015 Acquisition June 30 70% 4
December 2015 Acquisition December 31 59% 4

On February 29, 2016, we acquired a 55% interest in an eight-clinic physical therapy practice. The purchase price for the 55% interest was $13.2 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in February 2017 and 2018. In addition, we acquired a single clinic practice in June 2016 for $50,000.

On January 31, 2015, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $6.7 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, one of which was paid in January 2016 and the other is due in January 2017. On April 30, 2015, we acquired a 70% interest in a three-clinic physical therapy practice. The purchase price was $4.7 million in cash and $150,000 in a seller note that is payable in two principal installments of $75,000 each, plus accrued interest, one of which was paid in April 2016 and the other is due in April 2017. On June 30, 2015, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price was $3.6 million in cash and $0.7 million in seller notes that are payable plus accrued interest, in June 2018. On December 31, 2015, we acquired a 59% interest in a four-clinic physical therapy practice. The purchase price was $4.6 million in cash and $400,000 in seller notes payable that are payable in two principal installments of an aggregate of $200,000 each, plus accrued interest, in December 2016 and 2017. In addition to the multi-clinic acquisitions, on August 31, 2015, we acquired a 60% interest in a single physical therapy clinic for $150,000 in cash and $50,000 in a seller note payable that is payable plus accrued interest in August 2016. The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.

Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

For the Three Months Ended June 30, 2016 June 30, 2015 For the Six Months Ended June 30, 2016 June 30, 2015
Number of clinics, at the end of period 516 501 516 501
Working Days 64 64 128 127
Average visits per day per clinic 25.6 24.4 25.2 23.6
Total patient visits 840,020 776,867 1,648,301 1,489,722
Net patient revenue per visit $105.27 $104.85 $105.25 $105.56

RESULTS OF OPERATIONS

Three Months Ended June 30, 2016 Compared to the Three Months Ended June 30, 2015

  • Net revenues increased to $90.4 million for the three months ended June 30, 2016 (“2016 Second Quarter”) from $83.3 million for the three months ended June 30, 2015 (“2015 Second Quarter”) primarily due to an increase in visits of 63,100 from 776,900 for the 2015 Second Quarter to 840,000 for the 2016 Second Quarter and increase in the average net patient revenue per visit for the 2016 Second Quarter to $105.27 from $104.85 in the 2015 Second Quarter.
  • Net income attributable to our common shareholders from operations prior to revaluation of redeemable non-controlling interests, net of tax (“operating results”) for the 2016 Second Quarter was $7.1 million versus $6.3 million for the 2015 Second Quarter. Operating results was $0.57 per diluted share for the 2016 period and $0.51 for the 2015 period. Total diluted shares were 12.5 million for the 2016 Second Quarter and 12.4 million for the 2015 Second Quarter.

Net Patient Revenues

  • Net patient revenues increased to $88.4 million for the 2016 Second Quarter from $81.5 million for the 2015 Second Quarter, an increase of $6.9 million, or 8.6%, due to visits of 44,700 from clinics opened or acquired between July 1, 2015 and June 30, 2016 (“New Clinics”) and an increase in visits of 18,400 from clinics opened or acquired prior to July 1, 2015 (“Mature Clinics”) and a slight increase in the net patient revenue per visit of $0.42.
  • Net patient revenues related to New Clinics amounted to $5.4 million for the 2016 Second Quarter. Net patient revenues for Mature Clinics increased by $1.5 million for the 2016 Second Quarter as compared to the 2015 Second Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues increased $0.2 million in the 2016 Second Quarter to $2.0 million from $1.8 million in the 2015 Second Quarter due to an increase in the number of physical therapy facilities managed for third parties.

Clinic Operating Costs

Clinic operating costs were $67.4 million, or 74.5% of net revenues, for the 2016 Second Quarter and $62.1 million, or 74.6% of net revenues, for the 2015 Second Quarter. The increase was primarily attributable to $4.3 million in operating costs of New Clinics and by an increase in operating costs of $1.0 million for Mature Clinics. Each component of clinic operating costs is discussed below:

Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $48.8 million for the 2016 Second Quarter from $44.4 million for the 2015 Second Quarter, an increase of $4.4 million, or 10.0%. Salaries and related costs for New Clinics amounted to $3.1 million for the 2016 Second Quarter. Salaries and related costs for Mature Clinics increased by $1.3 million for the 2016 Second Quarter as compared to the 2015 Second Quarter. Salaries and related costs as a percentage of net revenues were 54.0% for the 2016 Second Quarter and 53.3% for the 2015 Second Quarter.

Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $17.5 million for the 2016 Second Quarter and $16.7 million for the 2015 Second Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $1.2 million for the 2016 Second Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other decreased by $0.4 million in the 2016 Second Quarter compared to the 2015 Second Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.4% for the 2016 Second Quarter and 20.0% for the 2015 Second Quarter.

Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.0 million for the 2016 Second Quarter and $1.1 million for the 2015 Second Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.1% for the 2016 Second Quarter and 1.3% for the 2015 Second Quarter.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 4.1% at June 30, 2016, as compared to 3.8% at December 31, 2015. Our day’s sales outstanding were 38 days at June 30, 2016 and 36 days at December 31, 2015.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $8.0 million for the 2016 Second Quarter and $7.6 million for the 2015 Second Quarter. As a percentage of net revenues, corporate office costs were 8.9% for the 2016 Second Quarter and 9.1% for the 2015 Second Quarter.

Interest Expense

Interest expense increased to $320,000 in the 2016 Second Quarter compared to $245,000 in the 2015 Second Quarter due to a higher average balance outstanding under our Amended Credit Agreement. At June 30, 2016, $42.5 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.

Provision for Income Taxes

The provision for income taxes was $4.7 million for the 2016 Second Quarter and $4.2 million for the 2015 Second Quarter. During the 2016 and 2015 Second Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.8% and 40.0%, respectively.

Non-controlling Interests

Net income attributable to non-controlling interests was $3.0 million for the 2016 Second Quarter and $2.8 million for the 2015 Second Quarter. As a percentage of operating income before corporate office costs, net income attributable to non-controlling interests was 13.0% for the 2016 Second Quarter and 13.3% for the 2015 Second Quarter.

Six Months Ended June 30, 2016 Compared to the Six Months Ended June 30, 2015

  • Net revenues increased to $177.3 million for the six months ended June 30, 2016 (“2016 First Six Months”) from $160.5 million for the six months ended June 30, 2015 (“2015 First Six Months”) primarily due to an increase in visits of 158,600 from 1,489,700 for the 2015 First Six Months to 1,648,300 for the 2016 First Six Months and offset by a slight decrease in the average net patient revenue per visit for the 2016 First Six Months to $105.25 from $105.56 in the 2015 First Six Months.
  • Operating results for the 2016 First Six Months were $12.4 million versus $10.5 million for the 2015 First Six Months. Operating results were $0.99 per diluted share for the 2016 period and $0.85 for the 2015 period. Total diluted shares were 12.5 million for the 2016 First Six Months and 12.4 million for the 2015 First Six Months.

Net Patient Revenues

  • Net patient revenues increased to $173.5 million for the 2016 First Six Months from $157.3 million for the 2015 First Six Months, an increase of $16.2 million, or 10.3%, due to visits of 71,300 from New Clinics and an increase in visits of 87,300 from Mature Clinics offset by a slight decrease in the net patient revenue per visit of $0.31.
  • Net patient revenues related to New Clinics amounted to $8.7 million for the 2016 First Six Months. Net patient revenues for Mature Clinics increased by $7.5 million for the 2016 First Six Months as compared to the 2015 First Six Months.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues increased $0.6 million in the 2016 First Six Months to $3.9 million from $3.3 million in the 2015 First Six Months due to an increase in the number of physical therapy facilities managed for third parties.

Clinic Operating Costs

Clinic operating costs were $133.8 million, or 75.4% of net revenues, for the 2016 First Six Months and $122.5 million, or 76.3% of net revenues, for the 2015 First Six Months. The increase was primarily attributable to $7.0 million in operating costs of New Clinics and by an increase in operating costs of $4.3 million for Mature Clinics. Each component of clinic operating costs is discussed below:

Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $96.6 million for the 2016 First Six Months from $87.5 million for the 2015 First Six Months, an increase of $9.1 million, or 10.5%. Salaries and related costs for New Clinics amounted to $5.0 million for the 2016 First Six Months. Salaries and related costs for Mature Clinics increased by $4.1 million for the 2016 First Six Months as compared to the 2015 First Six Months. Salaries and related costs as a percentage of net revenues were 54.5% for both periods.

Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $35.1 million for the 2016 First Six Months and $33.0 million for the 2015 First Six Months. For New Clinics, rent, clinic supplies, contract labor and other amounted to $2.0 million for the 2016 First Six Months. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $0.1 million in the 2016 First Six Months compared to the 2015 First Six Months. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.8% for the 2016 First Six Months and 20.6% for the 2015 First Six Months.

Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $2.0 million for the 2016 First Six Months and $2.1 million for the 2015 First Six Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.2% for the 2016 First Six Months and 1.3% for the 2015 First Six Months.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 4.1% at June 30, 2016, as compared to 3.8% at December 31, 2015. Our day’s sales outstanding were 38 days at June 30, 2016 and 36 days at December 31, 2015.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $17.0 million for the 2016 First Six Months and $15.3 million for the 2015 First Six Months. As a percentage of net revenues, corporate office costs were 9.6% for the 2016 First Six Months and 9.5% for the 2015 First Six Months.

Interest Expense

Interest expense increased to $628,000 in the 2016 First Six Months compared to $510,000 in the 2015 First Six Months due to a higher average balance outstanding under our Amended Credit Agreement. At June 30, 2016, $42.5 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.

Provision for Income Taxes

The provision for income taxes was $8.2 million for the 2016 First Six Months and $7.0 million for the 2015 First Six Months. During the 2016 and 2015 First Six Months, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.8% and 40.0%, respectively.

Non-controlling Interests

Net income attributable to non-controlling interests was $5.3 million for the 2016 First Six Months and $4.8 million for the 2015 First Six Months. As a percentage of operating income before corporate office costs, net income attributable to non-controlling interests was 12.3% for the 2016 First Six Months and 12.6% for the 2015 First Six Months.

LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At June 30, 2016 and December 31, 2015, we had $20.5 million and $15.8 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least June 2017. Significant acquisitions would likely require additional financing.

Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018. This agreement was amended in August 2015 and January 2016 and is hereinafter referred to as the “Amended Credit Agreement”. The Amended Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement. On June 30, 2016, $42.5 million was outstanding on the revolving credit facility resulting in $82.5 million of availability, and we were in compliance with all of the covenants thereunder.

The increase in cash and cash equivalents of $4.7 million from December 31, 2015 to June 30, 2016 was due primarily to $33.4 million provided by operations and $1.5 million of net proceeds from our Amended Credit Agreement. The major uses of cash for investing and financing activities included: purchase of businesses ($13.0 million), distributions to non-controlling interests ($5.2 million), funding of cash dividends to our shareholders ($4.3 million), purchases of fixed assets ($3.5 million), acquisitions of non-controlling interests ($1.4 million), and payments on notes payable ($0.5 million).

On February 29, 2016, we acquired a 55% interest in an eight-clinic physical therapy practice. The purchase price for the 55% interest was $13.2 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in February 2017 and 2018.

On December 31, 2015, we acquired a 59% interest in a four-clinic physical therapy practice. The purchase price was $4.6 million in cash and $0.4 million in seller notes payable that are payable in two principal installments of an aggregate of $200,000 each, plus accrued interest, in December 2016 and 2017. On June 30, 2015, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price was $3.6 million in cash and $0.7 million in seller notes that are payable plus accrued interest, in June 2018. On April 30, 2015, we acquired a 70% interest in a three-clinic physical therapy practice. The purchase price was $4.7 million in cash and $150,000 in a seller note that is payable in two principal installments of $75,000 each, plus accrued interest, one of which was paid in April 2016 and the other one is due in April 2017. On January 31, 2015, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $6.7 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, one of which was paid in January 2016 and the other one is due in January 2017. In addition to the multi-clinic acquisitions, on August 31, 2015, we acquired a 60% interest in a single physical therapy clinic for $150,000 in cash and $50,000 in a seller note payable that is payable plus accrued interest in August 2016.

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions. Our present outstanding notes payable relate to certain of the acquisitions of businesses and purchases of non-controlling interests that occurred in 2014 through June 2016. For those acquisitions, we entered into several notes payables aggregating $6.4 million. Typically, the notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 3.5% per annum, subject to adjustment. At June 30, 2016, the balance on these notes payable was $5.6 million. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is between three and five years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

As of June 30, 2016, we have accrued $2.1 million related to credit balances due to patients and payors. This amount is expected to be paid in the next twelve months.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with convenants. We are required to retire shares purchased under the March 2009 Authorization.

There is no expiration date for the share repurchase program. As of June 30, 2016, there are currently an additional estimated 249,128 shares (based on the closing price of $60.21 on June 30, 2016) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the six months ended June 30, 2016.

FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

  • changes as the result of government enacted national healthcare reform;
  • changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
  • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
  • business and regulatory conditions including federal and state regulations;
  • governmental and other third party payor investigations and audits;
  • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
  • possible legal actions, which could subject us to increased costs and uninsured liabilities;
  • changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
  • revenue and earnings expectations;
  • general economic conditions;
  • availability and cost of qualified physical therapists;
  • personnel productivity and retaining key personnel;
  • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
  • acquisitions including the purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
  • maintaining adequate internal controls;
  • maintaining adequate insurance coverage;
  • availability, terms, and use of capital; and
  • weather and other seasonal factors.

See Risk Factors in Item 1A of our Annual Report on Form 10-K.

Forward-Looking Statements

We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as (the “Exchange Act”). These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

  • changes as the result of government enacted national healthcare reform;
  • changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
  • revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
  • business and regulatory conditions including federal and state regulations;
  • governmental and other third party payor investigations and audits;
  • compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
  • possible legal actions, which could subject us to increased costs and uninsured liabilities;
  • changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
  • revenue and earnings expectations;
  • general economic conditions;
  • availability and cost of qualified physical therapists;
  • personnel productivity and retaining key personnel;
  • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
  • acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
  • maintaining adequate internal controls;
  • maintaining necessary insurance coverage;
  • availability, terms, and use of capital; and
  • weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.

Market risk

As filed, 581 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Amended Credit Agreement. The interest on our Amended Credit Agreement is based on a variable rate. At June 30, 2016, $42.5 million was outstanding under our Amended Credit Agreement. Based on the balance of the Amended Credit Agreement at June 30, 2016, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $425,000.

Controls and procedures

As filed, 1,386 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-04-01 to 2016-06-30$90.4mus-gaap:SalesRevenueNet
Revenue6 months2016-01-01 to 2016-06-30$177.3mus-gaap:SalesRevenueNet
Gross profit3 months2016-04-01 to 2016-06-30$23.1mus-gaap:GrossProfit
Gross profit6 months2016-01-01 to 2016-06-30$43.6mus-gaap:GrossProfit
Selling, general and administrative3 months2016-04-01 to 2016-06-30$8.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2016-01-01 to 2016-06-30$17.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-04-01 to 2016-06-30$15.0mus-gaap:OperatingIncomeLoss
Operating income6 months2016-01-01 to 2016-06-30$26.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-04-01 to 2016-06-30$320.0kus-gaap:InterestExpense
Interest expense6 months2016-01-01 to 2016-06-30$628.0kus-gaap:InterestExpense
Income tax3 months2016-04-01 to 2016-06-30$4.7mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2016-01-01 to 2016-06-30$8.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-04-01 to 2016-06-30$7.1mus-gaap:NetIncomeLoss
Net income6 months2016-01-01 to 2016-06-30$12.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-04-01 to 2016-06-30$0.57us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2016-01-01 to 2016-06-30$0.99us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-04-01 to 2016-06-30$0.57us-gaap:EarningsPerShareBasic
Basic EPS6 months2016-01-01 to 2016-06-30$0.99us-gaap:EarningsPerShareBasic
Capital expenditure6 months2016-01-01 to 2016-06-30$3.5mus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid6 months2016-01-01 to 2016-06-30$4.3mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2016-06-30$20.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$70.4mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$313.6mus-gaap:Assets
Current liabilitiesAt period end2016-06-30$29.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$90.5mus-gaap:Liabilities
Long-term debtAt period end2016-06-30$47.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2016-06-30$1.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2016-06-30$173.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-16-074937. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.